Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Runge, V. M.
Right arrow Articles by Harms, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Runge, V. M.
Right arrow Articles by Harms, S. E.

Radiology, Vol 181, 701-709, Copyright © 1991 by Radiological Society of North America

ARTICLES

Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease

VM Runge, WG Bradley, MN Brant-Zawadzki, MJ Carvlin, DN DeSimone, BL Dean, WP Dillon, BP Drayer, AE Flanders and SE Harms
Department of Diagnostic Radiology, University of Kentucky Chandler Medical Center, Lexington.

In this phase III study, 411 adult patients with suspected intracranial or spinal disease underwent magnetic resonance (MR) imaging before and after intravenous injection of 0.1 mmol/kg gadoteridol (gadolinium 1,4,7-tris [carboxymethyl]-10-[2'-hydroxypropyl]-1,4,7,10- tetraazacyclododecane+ ++). MR images were evaluated by a single unblinded reader at each of 27 sites; the diagnosis was confirmed with one of nine imaging or surgical procedures within 8 weeks before or after MR imaging. After injection, no clinically significant changes were noted in laboratory values, physical examination, or vital signs. Adverse clinical events possibly or probably associated with injection of gadoteridol were seen in 18 of 411 patients (4.4%); the most common were dysgeusia and mild nausea, and all abated without residual effects. MR images enhanced with gadoteridol in patients with confirmed disease provided more diagnostic information than unenhanced images in 128 of 175 brain examinations (73.1%) and 93 of 137 spinal examinations (67.9%). A change in diagnosis because of additional information from contrast-enhanced images was considered likely in 63 of 214 cranial and 54 of 161 spinal studies.


This article has been cited by other articles:


Home page
 Br. J. Radiol.Home page
C Lohrmann, E Foeldi, J-P Bartholomae, and M Langer
Gadoteridol for MR imaging of lymphatic vessels in lymphoedematous patients: initial experience after intracutaneous injection
Br. J. Radiol., July 1, 2007; 80(955): 569 - 573.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
V. M. Runge and L. Berlin
Allergic Reactions to Gadolinium Chelates
Am. J. Roentgenol., October 1, 2001; 177(4): 944 - 945.
[Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
J. Breslau, J. G. Jarvik, D. R. Haynor, W. T. Longstreth Jr, D. L. Kent, and K. R. Maravilla
MR Contrast Media in Neuroimaging: A Critical Review of the Literature
AJNR Am. J. Neuroradiol., April 1, 1999; 20(4): 670 - 675.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1991 by the Radiological Society of North America.